Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Esperion Therapeutics Inc.

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Esperion today and set a price target of $16.00. According to TipRanks, Pantgin...

Esperion (ESPR) Gets a Buy from H.C. Wainwright

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Esperion, with a price target of $9.00. According to TipRa...

Current Quarter	$0.16	Next Quarter	$-0.09
Current Year	$-0.08	Next Year	$0.13
QoQ Growth	-156.3%	YoY Growth	+262.5%
3Y EPS CAGR	+68.9%	Target Price	$6.46
Consensus	Buy	Upside	+84.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ESPR	$3.50	+3.24%	3.95M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ESPR	$3.50	+3.2%	3.95M
3
4
5
6

ESPR

ESPR

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Esperion Therapeutics Inc. Data in Excel

Get Esperion Therapeutics Inc. Data in Excel